AI Article Synopsis
- The association between Myelodysplasia (MDS) and multiple myeloma (MM) can occur without prior chemotherapy and complicates treatment options.
- A case was reported where a patient was diagnosed with both conditions simultaneously; treatment with VTD (bortezomib, thalidomide, dexamethasone) showed strong anti-myeloma effects but led to a quick progression of MDS to acute myeloid leukemia (AML).
- This case suggests that while VTD can combat MM, it is not effective for managing MDS and highlights the need for more research into therapies for patients with both MDS and MM.
Article Abstract
The association of Myelodysplasia (MDS) and multiple myeloma (MM) has been usually described not only as a complication of chemotherapy but also in the absence of preceding chemotherapy or together at the time of diagnosis. Optimal therapies of a coexisting MM and MDS have not been well established up to now. We report a case of MDS diagnosed simultaneously with MM. After treatment with VTD (bortezomib, thalidomide, dexamethasone) marked anti-myeloma activity was observed, but it was associated with rapid progression of the MDS to acute myeloid leukemia (AML). The leukemic transformation in our case most probably reflects the natural progression of MDS, though it clearly demonstrates that VTD is ineffective in controlling blast proliferation in MDS. To our knowledge, this is the first case report on MDS in the setting of MM with rapid evolution to AML to VTD therapy. More data from more cases are needed, to find the potential utility of VTD therapy in coexisting MDS and MM patients.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4538129 | PMC |
Publication Analysis
Top Keywords
Similar Publications
The evolving treatment landscape of multiple myeloma in Portugal: A nation-wide retrospective cohort study of real-world clinical practice.
EJHaem
December 2024
Johnson & Johnson Innovative Medicine Lisbon Portugal.
Objectives: To characterize variations in real-world treatment patterns in multiple myeloma (MM) in Portugal over a 5-year period.
Methods: A retrospective cohort multicenter study using secondary data of national hospital drug consumption database from 11 Portuguese public hospitals between 2017 and 2022.
Results: Number of MM-treated patients increased 53% over 5 years (from 825 to 1266 patients).
Article Synopsis
- Advances in colorectal cancer (CRC) treatment face challenges due to fast tumor spread and screening issues, especially for early-onset CRC, highlighting the need for better therapies.
- The Rictor-mTORC2-AKT pathway is critical in promoting metastasis, and selective inhibitors targeting mTORC2, like Veratridine (VTD), show promise in reducing tumor growth and metastasis.
- VTD acts by destabilizing Rictor, leading to decreased cancer stem cell populations and aggressive tumor behaviors in CRC, offering a new potential approach to treatment.
First-Line Use of Daratumumab in Patients with Multiple Myeloma Shows Delayed Neutrophil and Platelet Engraftment after Autologous Stem Cell Transplantation: Results from a Real-Life Single-Center Study.
Cancers (Basel)
September 2024
Institute of Clinical Physiology (IFC-CNR), Section of Rome, 00185 Rome, Italy.
Article Synopsis
- This study examined the effects of D-VTd induction therapy on recovery after autologous stem cell transplantation in patients with newly diagnosed multiple myeloma (NDMM).
- Sixty patients received D-VTd while 80 others received VTd as a control, with results showing that D-VTd led to a slightly longer time for neutrophil and platelet recovery.
- Despite delayed engraftment in the D-VTd group and a higher incidence of febrile neutropenia, the study concluded that D-VTd does not negatively affect overall transplant safety outcomes.
Evaluating a novel vertical traction device for early closure in open abdomen management: a consecutive case series.
Front Surg
August 2024
Department of General, Visceral and Transplantation Surgery, RWTH Aachen University Hospital, Aachen, Germany.
Article Synopsis
- - The study explores the effectiveness of a new device called the vertical traction device (VTD) in facilitating early definitive fascial closure (DFC) for patients with an open abdomen due to abdominal compartment syndrome (ACS).
- - Out of nine patients who were treated, six successfully achieved DFC, with the VTD significantly reducing the distance between fascia until closure, while not impacting ventilation or other critical health metrics adversely.
- - Although three patients died before DFC and some experienced mild skin irritation, the study concludes that the VTD is a promising and safe tool for improving outcomes in emergency surgical cases involving open abdomens.
Effects of daratumumab on hematopoietic stem cell collection and engraftment in multiple myeloma patients eligible for autologous transplantation: results of the real-life PRIMULA study comparing bortezomib, thalidomide and dexamethasone (VTd) with VTd plus daratumumab (D-VTd) as induction therapy.
Ann Hematol
October 2024
Department of Precision and Regenerative Medicine and Ionian Area, Aldo Moro University School of Medicine, Bari, Italy.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!